• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Enhanced Costimulation Blockade With αCD154, αCD2, and αCD28 to Promote Heart Allograft Tolerance in Nonhuman Primates.使用αCD154、αCD2和αCD28增强共刺激阻断以促进非人灵长类动物心脏同种异体移植耐受
Transplantation. 2025 Jun 1;109(6):e287-e296. doi: 10.1097/TP.0000000000005315. Epub 2025 Jan 9.
2
Cardiac allograft tolerance can be achieved in nonhuman primates by donor bone marrow and kidney cotransplantation.通过供体骨髓和肾脏联合移植,可在非人灵长类动物中实现心脏同种异体移植耐受。
Sci Transl Med. 2025 Jan 22;17(782):eads0255. doi: 10.1126/scitranslmed.ads0255.
3
Successful Induction of Specific Immunological Tolerance by Combined Kidney and Hematopoietic Stem Cell Transplantation in HLA-Identical Siblings.HLA 同基因兄弟姐妹间联合肾和造血干细胞移植诱导特异性免疫耐受的成功。
Front Immunol. 2022 Jan 31;13:796456. doi: 10.3389/fimmu.2022.796456. eCollection 2022.
4
Belatacept for kidney transplant recipients.用于肾移植受者的贝拉西普。
Cochrane Database Syst Rev. 2014 Nov 24;2014(11):CD010699. doi: 10.1002/14651858.CD010699.pub2.
5
Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.肝移植受者的抗体诱导与安慰剂、无诱导或另一种抗体诱导方式的比较。
Cochrane Database Syst Rev. 2014 Jun 5;2014(6):CD010253. doi: 10.1002/14651858.CD010253.pub2.
6
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.用于肾移植受者诱导治疗的多克隆抗体和单克隆抗体。
Cochrane Database Syst Rev. 2017 Jan 11;1(1):CD004759. doi: 10.1002/14651858.CD004759.pub2.
7
Differential induction of donor-reactive Foxp3 regulatory T cell via blockade of CD154 vs CD40.通过阻断 CD154 与 CD40 实现供者反应性 Foxp3 调节性 T 细胞的差异诱导。
Am J Transplant. 2024 Aug;24(8):1369-1381. doi: 10.1016/j.ajt.2024.03.033. Epub 2024 Mar 27.
8
Hematopoietic cell-based and non-hematopoietic cell-based strategies for immune tolerance induction in living-donor renal transplantation: A systematic review.基于造血细胞和非造血细胞的活体供肾移植免疫耐受诱导策略:一项系统综述。
Transplant Rev (Orlando). 2023 Dec;37(4):100792. doi: 10.1016/j.trre.2023.100792. Epub 2023 Aug 19.
9
Sex and gender as predictors for allograft and patient-relevant outcomes after kidney transplantation.性别作为肾移植后同种异体移植及患者相关预后的预测因素。
Cochrane Database Syst Rev. 2024 Dec 19;12(12):CD014966. doi: 10.1002/14651858.CD014966.pub2.
10
Immunosuppressive T-cell antibody induction for heart transplant recipients.心脏移植受者的免疫抑制性T细胞抗体诱导治疗
Cochrane Database Syst Rev. 2013 Dec 2;2013(12):CD008842. doi: 10.1002/14651858.CD008842.pub2.

本文引用的文献

1
Intragraft B cell differentiation during the development of tolerance to kidney allografts is associated with a regulatory B cell signature revealed by single cell transcriptomics.在同种异体肾移植耐受的发展过程中,移植肾内 B 细胞的分化与单细胞转录组学揭示的调节性 B 细胞特征有关。
Am J Transplant. 2023 Sep;23(9):1319-1330. doi: 10.1016/j.ajt.2023.05.036. Epub 2023 Jun 8.
2
TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival.TNX-1500,一种可结晶片段修饰的抗 CD154 抗体,可延长非人灵长类心脏移植物的存活时间。
Am J Transplant. 2023 Aug;23(8):1182-1193. doi: 10.1016/j.ajt.2023.03.025. Epub 2023 Apr 7.
3
Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies.移植后淋巴组织增生性疾病:治疗和新疗法的最新进展。
Br J Haematol. 2023 May;201(3):383-395. doi: 10.1111/bjh.18763. Epub 2023 Mar 22.
4
A Mixed-chimerism Protocol Utilizing Thymoglobulin and Belatacept Did Not Induce Lung Allograft Tolerance, Despite Previous Success in Renal Allotransplantation.尽管之前在肾脏同种异体移植中取得了成功,但使用胸腺球蛋白和贝拉西普的混合嵌合方案并未诱导肺移植耐受。
Transplant Direct. 2021 May 25;7(6):e705. doi: 10.1097/TXD.0000000000001150. eCollection 2021 Jun.
5
The Importance of Bringing Transplantation Tolerance to the Clinic.将移植耐受引入临床的重要性。
Transplantation. 2021 May 1;105(5):935-940. doi: 10.1097/TP.0000000000003532.
6
Kidney-induced systemic tolerance of heart allografts in mice.肾诱导的小鼠心脏同种异体移植物的全身耐受。
JCI Insight. 2020 Sep 17;5(18):139331. doi: 10.1172/jci.insight.139331.
7
Inducing Transient Mixed Chimerism for Allograft Survival Without Maintenance Immunosuppression With Combined Kidney and Bone Marrow Transplantation: Protocol Optimization.诱导混合嵌合体以实现同种异体移植物存活而无需联合肾和骨髓移植的维持性免疫抑制:方案优化。
Transplantation. 2020 Jul;104(7):1472-1482. doi: 10.1097/TP.0000000000003006.
8
Pharmacokinetic and pharmacodynamic study of a clinically effective anti-CD2 monoclonal antibody.临床有效抗 CD2 单克隆抗体的药代动力学和药效学研究。
Scand J Immunol. 2020 Jan;91(1):e12839. doi: 10.1111/sji.12839. Epub 2019 Nov 10.
9
Long-term Nonhuman Primate Renal Allograft Survival Without Ongoing Immunosuppression in Recipients of Delayed Donor Bone Marrow Transplantation.延迟供者骨髓移植受者中无持续免疫抑制的长期非人类灵长类肾移植存活。
Transplantation. 2018 Apr;102(4):e128-e136. doi: 10.1097/TP.0000000000002078.
10
Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach.通过混合嵌合体方法实现移植耐受的临床前和临床研究。
Hum Immunol. 2018 May;79(5):258-265. doi: 10.1016/j.humimm.2017.11.008. Epub 2017 Nov 22.

使用αCD154、αCD2和αCD28增强共刺激阻断以促进非人灵长类动物心脏同种异体移植耐受

Enhanced Costimulation Blockade With αCD154, αCD2, and αCD28 to Promote Heart Allograft Tolerance in Nonhuman Primates.

作者信息

Chaban Ryan, Ileka Ikechukwu, Kinoshita Kohei, McGrath Gannon, Habibabady Zahra, Ma Madelyn, Diaz Victoria, Maenaka Akihiro, Rosales Ivy, Lederman Seth, Tkachev Victor, Madsen Joren C, Pierson Richard N

机构信息

Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Department of Cardiovascular Surgery, University Hospital of Mainz, Mainz, Germany.

出版信息

Transplantation. 2025 Jun 1;109(6):e287-e296. doi: 10.1097/TP.0000000000005315. Epub 2025 Jan 9.

DOI:10.1097/TP.0000000000005315
PMID:39792548
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12097961/
Abstract

BACKGROUND

Long-term renal allograft acceptance has been achieved in macaques using a transient mixed hematopoetic chimerism protocol, but similar regimens have proven unsuccessful in heart allograft recipients unless a kidney transplant was performed simultaneously. Here, we test whether a modified protocol based on targeting CD154, CD2, and CD28 is sufficient to prolong heart allograft acceptance or promote the expansion of regulatory T cells.

METHODS

Eight macaques underwent heterotopic allo-heart transplantation from major histocompatibility complex-mismatched donors. Induction treatment for donor bone marrow transplantation (BMT) was administered after a 4-mo delay period under TNX-1500 monotherapy. The BMT induction regimen comprised 1 (group 1, G1; n = 3) or 2 (group 2, G2; n = 5) doses of total body irradiation, thymic irradiation, and antithymocyte globulin, followed by 2 (G1) or 5 (G2) weekly doses of αCD2 and 5 weekly treatments with αCD28 and TNX-1500.

RESULTS

During the delay period, 1 G1 graft was rejected and 2 (1 in each group) exhibited moderate rejection on protocol biopsy before BMT. Lymphocyte chimerism was seen in 3 of 5 G2 animals and in 1 of 2 G1 recipients. One G1 graft was rejected despite chimerism, whereas the other recipient succumbed to anti-cytomegalovirus treatment. Two G2 monkeys succumbed due to infection (cytomegalovirus, bacteremia) post-BMT and 3 due to posttransplantation lymphoproliferative disease.

CONCLUSIONS

Intensive costimulation pathway blockade with αCD2, αCD154, and αCD28 promotes lymphocyte chimerism at the cost of high incidence of posttransplantation lymphoproliferative disease and opportunistic infections, preventing assessment of the effectiveness of the regimen to promote alloimmune tolerance.

摘要

背景

在猕猴中,通过短暂混合造血嵌合方案已实现长期肾移植接受,但类似方案在心脏移植受者中被证明是不成功的,除非同时进行肾移植。在此,我们测试基于靶向CD154、CD2和CD28的改良方案是否足以延长心脏移植接受时间或促进调节性T细胞的扩增。

方法

八只猕猴接受了来自主要组织相容性复合体不匹配供体的异位同种异体心脏移植。在TNX - 1500单药治疗4个月的延迟期后,进行供体骨髓移植(BMT)的诱导治疗。BMT诱导方案包括1次(第1组,G1;n = 3)或2次(第2组,G2;n = 5)全身照射、胸腺照射和抗胸腺细胞球蛋白,随后每周2次(G1)或5次(G2)给予αCD2,以及每周5次给予αCD28和TNX - 1500治疗。

结果

在延迟期,1例G1移植被排斥,2例(每组1例)在BMT前的方案活检中表现为中度排斥。5例G2动物中有3例和2例G1受者中有1例出现淋巴细胞嵌合。1例G1移植尽管出现嵌合仍被排斥,而另1例受者死于抗巨细胞病毒治疗。2例G2猕猴在BMT后因感染(巨细胞病毒、菌血症)死亡,3例因移植后淋巴细胞增生性疾病死亡。

结论

用αCD2、αCD154和αCD28进行强化共刺激途径阻断可促进淋巴细胞嵌合,但代价是移植后淋巴细胞增生性疾病和机会性感染的高发生率,从而妨碍了对该方案促进同种免疫耐受有效性的评估。